Author(s): N. Dhanesh Kumar, M. Ganesh Prasath, R. Sangamithra, K. Janani

Email(s): ddhanesh21@gmail.com , tjgp2002madurai@gmail.com , sandhya2002siva@gmail.com , kathiresanjanani9@gmail.com

DOI: 10.52711/ijnmr.2026.46   

Address: N. Dhanesh Kumar1, M. Ganesh Prasath2, R. Sangamithra3, K. Janani4
1Assistant Professor, Department of Medical Surgical Nursing, Sacred Heart Nursing College, Madurai, Affiliated to The Tamil Nadu Dr. M.G.R. Medical University, Chennai, India.
2,3,4Nursing Tutor, Department of Medical Surgical Nursing, Sacred Heart Nursing College, Madurai, Affiliated to The Tamil Nadu Dr. M.G.R. Medical University, Chennai, India.
*Corresponding Author

Published In:   Volume - 5,      Issue - 4,     Year - 2026


ABSTRACT:
Neurofibromatosis (NF) is among the most common genetic disorders. It is inherited in an autosomal dominant manner and belongs to the group of phacomatoses. NF is divided into two genetically distinct subtypes, each characterized by multiple cutaneous lesions and tumors affecting the peripheral and central nervous systems. Neurofibromatosis type 1(NF1), also known as Recklinghausen's disease, occurs in approximately 1 in 3,500 individuals and is associated with various characteristic abnormalities of the skin and peripheral nervous system. Neurofibromatosis type 2(NF2), previously called central neurofibromatosis, is much rarer, with a prevalence of less than 1 in 25,000 individuals. Clinical signs of NF2 often appear in late adolescence, frequently presenting as sudden hearing loss due to the development of bilateral or unilateral vestibular schwannomas. Additionally, patients with NF2 may develop other nervous system tumors, including meningiomas or gliomas. This review highlights the distinguishing features of both NF subtypes and discusses the similarities and differences between NF1 and NF2.


Cite this article:
N. Dhanesh Kumar, M. Ganesh Prasath, R. Sangamithra, K. Janani. Neurofibromatosis: Contemporary Insights and Emerging Horizons. A and V Pub International Journal of Nursing and Medical Research.2026; 5(4):227-2. doi: 10.52711/ijnmr.2026.46

Cite(Electronic):
N. Dhanesh Kumar, M. Ganesh Prasath, R. Sangamithra, K. Janani. Neurofibromatosis: Contemporary Insights and Emerging Horizons. A and V Pub International Journal of Nursing and Medical Research.2026; 5(4):227-2. doi: 10.52711/ijnmr.2026.46   Available on: https://ijnmronline.com/AbstractView.aspx?PID=2026-5-4-12


REFERENCES:
1.    Gerber, P., Antal, A., Neumann, N., Homey, B., Matuschek, C., Peiper, M., Budach, W., and Bölke, E. Neurofibromatosis. European Journal of Medical Research. 2009; 14(3): 102–105. https://doi.org/10.1186/2047-783x-14-3-102
2.    Zanca, A. Antique illustrations of NF1. International Journal of Dermatology. 1980; 19: 55 https://doi.org/10.1111/j.1365-4362.1980.tb01998.x
3.    Huson, S. M., Compston, D. A. and Harper, P. S. A genetic study of von Recklinghausen NF1 in southeast Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. Journal of Medical Genetics. 1989; 26: 712 https://doi.org/10.1136/jmg.26.11.712
4.    Cawthon, R. M., Weiss, R., Xu, G. F. et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell. 1990; 62: 193 10.1016/0092-8674(90)90253-B 
5.    Britannica Editors (2025, December 15). neurofibromatosis. Encyclopedia Britannica. https://www.britannica.com/science/ neurofibromatosis
6.    Lee, TS.J., Chopra, M., Kim, R.H. et al. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet J Rare Dis. 2023;18: 292. https://doi.org/ 10.1186/s13023-023-02911-2
7.    Almuqbil M, et al. Epidemiology and outcomes of neurofibromatosis type 1. J Multidiscip Healthc. 2024. 
8.    Liang W, et al. Long-term distress and health outcomes in NF1. Front Public Health. 2024. 
9.    Moodley M, et al. Neurofibromatosis type 2-related schwannomatosis. Clin Neurol Neurosurg. 2024. 
10.    Lee TSJ, et al. Epidemiological estimates of NF1 and NF2. Orphanet J Rare Dis. 2023.
11.    Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017; 3: 17004. 
12.    Evans DG. Neurofibromatosis type 2. Handb Clin Neurol. 2015; 132: 87–96.
13.    Legius E, et al. Revised diagnostic criteria for NF1. Genet Med. 2021.
14.    Evans DG, et al. Diagnostic criteria for NF2. J Med Genet. 2005.
15.    National Institutes of Health Consensus Development Conference. Neurofibromatosis. NIH Consens Statement. 1987.
16.    Liu, Yan; Zhang, Xianan PhD; Jiang, Chunchao PhD; Yang, Xizhi; Luo, Wenfu; Ai, Yunzhi; Zhang, Lin. Diagnosis, treatment management, and challenges in neurofibromatosis type 1: a case report with mixed features. Annals of Medicine and Surgery. 2026; 88(2): 1907-1912, DOI: 10.1097/MS9.0000000000004521 
17.    K. Anbarasu, P. Jagadeeswari, Radha Mahendran. In-silico Screening of Deleterious NF1 SNPs Associated with Neurofibromatosis Type I. Research J. Pharm. and Tech. 2017; 10(9): 3247-3250.
18.    B. Rajasekar. Brain Tumour Segmentation using CNN and WT. Research J. Pharm. and Tech. 2019; 12(10): 4613-4617.
19.    OpenAI. (2026). ChatGPT (Version GPT-5) [Large language model]. https://chatgpt.com/

Recomonded Articles:

A and V Pub International Journal of Nursing and Medical Research (IJNMR) is an international, peer-reviewed journal devoted to nursing and medical sciences. IJNMR's aim is to promote excellence in nursing and health care through the publication of clinical information and original research....... Read more >>>

RNI:                      
DOI:  


Journal Policies & Information



Popular Articles


Recent Articles




Tags